Replies to post #163152 on Biotech Values

[jq1234]

I was pretty sure they were the same product with two different brand names. To confirm this, I just went through HSP's last 10Q, here they are on page 21:

Celltrion completed its biosimilar development program for infliximab and submitted a dossier, and Hospira submitted a duplicate dossier, to the European Medicines Agency (“EMA”) in the first half of 2012. Celltrion submitted two dossiers for infliximab to Health Canada in late 2012;

http://www.hospirainvestor.com/phoenix.zhtml?c=175550&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTg4OTEyMzImRFNFUT0wJlNFUT0wJlNRREVTQz1TRUNUSU9OX0VOVElSRSZzdWJzaWQ9NTc%3d